What is the structural difference between growth capital and venture capital?

Stage (post-PMF vs pre-PMF), risk model (revenue compounding vs power-law), term-sheet weight (lighter protective rights vs compounding preferences), and time horizon (flexible vs locked to fund cycle). The instruments are not interchangeable; choosing the wrong one for the stage costs the founder dilution and operating optionality.

When should a B2B SaaS company switch from VC to growth capital?

Once NRR is reliably above 105%, acquisition is repeatable, and the company has a credible 24-month operating thesis where execution rather than demand discovery is the binding constraint. Below those thresholds, growth-capital firms will pass; above them, the dilution math favours growth capital.

Will a growth-capital round take more or less equity than a Series B VC round?

Typically less. The pricing reflects lower risk (post-PMF vs pre-PMF) and the round is sized to the operating thesis rather than to a 5-year power-law return target. €3M of growth capital at €1M ARR with NRR > 110% typically takes 12–18% equity; the comparable Series B VC round often takes 18–25%.

Which has stronger founder protections - growth capital or venture capital?

Growth capital, on average. Term sheets at the post-PMF stage are lighter on protective consents because the operational risk is lower; founders retain more control. The exception is operator-led growth capital where governance overhead is heavier in exchange for embedded operating support - a trade founders should evaluate explicitly.

Insights / Growth Capital vs Venture Capital

By Gaute Green-StensrudPublished 11 Apr 2026Updated 8 May 2026

Growth capital vs venture capital, decided.

For B2B SaaS founders past €1M ARR, the right instrument depends on the binding constraint - and the dilution math turns asymmetric quickly. This is the practical decision frame.

The structural distinction

Venture capital is a power-law instrument. Funds expect a small fraction of investments to return the entire fund; the rest can fail. The portfolio mathematics drive everything - large markets, ambitious growth bets, dilutive term sheets that compound preferences. The structure is appropriate when the binding risk is whether the product can find a market at all.

Growth capital is a revenue-compounding instrument. Most investments are expected to return capital with operating-leverage gains. The portfolio mathematics tolerate narrower variance, the term sheets are lighter, and the time horizon is flexible. The structure is appropriate when product-market fit is established and the binding risk is whether the company can scale execution.

The stage threshold

The transition from VC-appropriate to growth-capital-appropriate is not a single event but a band, typically €1M–€3M ARR for B2B SaaS. Three signals indicate the switch:

NRR > 105% over a trailing 12 months. Below this, the company is still proving expansion economics.
Repeatable customer acquisition across more than one channel or segment. A single-channel-dependent business is still discovering its motion.
Operating thesis articulated with milestone clarity. A founder who can describe what the next 24 months looks like in operating terms (hires, products, regions) is past the "discovery" phase.

The dilution math

At post-PMF stages, growth capital prices below VC for the same operating profile. The reason is risk: a B2B SaaS company at €1M ARR with NRR > 110% is materially less risky than the same company at €0M ARR. Growth-capital firms can pay the higher price-to-revenue multiple that lower risk supports without giving up returns.

For a founder, the practical implication is that switching from a VC funding path to a growth-capital path at the right moment can reduce total dilution at €5M ARR by 5–15 percentage points. Across a six-year hold, that compounds.

Term-sheet weight

VC term sheets at Series A and B compound preferences, protective rights, and supermajority consents because the early-stage risk justifies it. Growth-capital term sheets at the post-PMF stage are typically lighter: 1× non-participating preferred (no participation), broad-based weighted-average anti-dilution, board composition proportionate to ownership, and the standard minority-protective consent list (M&A above thresholds, change of control, share issuance dilutive of the lead, senior-comp above bands, indebtedness above 1× ARR). Anything beyond that is over-reach for the stage.

Operator-led capital as a third option

The instrument has a third variant relevant for post-PMF B2B SaaS: operator-led growth capital, where minority capital is paired with embedded delivery teams (engineers, GTM operators, governance specialists) under a written operating thesis. The structure addresses the systematic under-investment in operating throughput by capital-only growth-equity funds. For founders whose binding constraint is execution rather than capital, the operator-paired model is structurally a better fit. See operator-led growth equity, explained.

How to decide

The decision frame: name the binding constraint on the next 18–24 months. If demand discovery is still incomplete, raise venture capital. If the constraint is capital alone (the operating capacity to use it is in place), raise capital-only growth equity. If the constraint is operating capacity itself, raise operator-led growth capital. Anything else is fitting the instrument to the founder’s preference rather than the company’s structural need.

Frequently asked questions

What is the structural difference between growth capital and venture capital?: Stage (post-PMF vs pre-PMF), risk model (revenue compounding vs power-law), term-sheet weight (lighter protective rights vs compounding preferences), and time horizon (flexible vs locked to fund cycle). The instruments are not interchangeable; choosing the wrong one for the stage costs the founder dilution and operating optionality.
When should a B2B SaaS company switch from VC to growth capital?: Once NRR is reliably above 105%, acquisition is repeatable, and the company has a credible 24-month operating thesis where execution rather than demand discovery is the binding constraint. Below those thresholds, growth-capital firms will pass; above them, the dilution math favours growth capital.
Will a growth-capital round take more or less equity than a Series B VC round?: Typically less. The pricing reflects lower risk (post-PMF vs pre-PMF) and the round is sized to the operating thesis rather than to a 5-year power-law return target. €3M of growth capital at €1M ARR with NRR > 110% typically takes 12–18% equity; the comparable Series B VC round often takes 18–25%.
Which has stronger founder protections - growth capital or venture capital?: Growth capital, on average. Term sheets at the post-PMF stage are lighter on protective consents because the operational risk is lower; founders retain more control. The exception is operator-led growth capital where governance overhead is heavier in exchange for embedded operating support - a trade founders should evaluate explicitly.

Speak with a partner Compare TGC vs VC